We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Study Finds Immunity to Coronavirus May Last Only Six Months with Reinfection Possible

By HospiMedica International staff writers
Posted on 30 May 2020
Illustration
Illustration
A study by the University of Amsterdam (Amsterdam, the Netherlands) has found that immunity to human coronaviruses may last for only six months with a possibility of reinfection.

These findings have raised doubts over the effectiveness of "immunity passports" to be issued by some governments to COVID-19 survivors based on the assumption that they cannot be reinfected and would contribute to reviving the economy.

In the study, the researchers monitored 10 men aged over 35 years to determine their antibody levels after they had been infected with any of the four seasonal human coronaviruses. The men, then aged 27 to 40-years old, were then tested at an interval of either three or six months. The researchers discovered an "alarmingly short duration of protective immunity to coronaviruses" and observed "frequent reinfections at 12 months post-infection and substantial reduction in antibody levels as soon as 6 months post-infection."

According to the researchers, the four strains of human coronaviruses are "biologically dissimilar" and “have little in common, apart from causing the common cold, although “they all seem to induce a short-lasting immunity with rapid loss of antibodies. This may well be a general denominator for human coronaviruses. If SARS-CoV-2 will behave like a seasonal coronavirus in the future, a similar pattern may be expected.” The researchers warned that "as protective immunity may be lost by 6 months post-infection, the prospect of reaching functional herd immunity by natural infection seems very unlikely.”

Related Links:
University of Amsterdam

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Endoscopy Display
E190

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more